Atossa Therapeutics Inc. (NASDAQ:ATOS) stock Rockets 565% YTD: Will it Hot $10?
Atossa Therapeutics Inc. (NASDAQ:ATOS) stock has been among the top-performing stocks this year, and it is up 565% year to date.
The Hyman Research Ethics Committee (HREC) gave the company regulatory approval to start a clinical trial for AT-H201 in Australia. At-H201 is a nebulized formulation the company is developing as an inhaler for hospitalized coronavirus patients and also for post-infection pulmonary “long-haul” disease patients. CEO Steven Quay said that if initial AT-H201 results are successful, the company will study the formulation’s efficacy in moderate COVID-19 cases that can be treated through a nebulizer.
Recently the company released successful findings from its mid-stage clinical study of a possible breast cancer treatment. Notably, the company’s flagship candidate, endoxifen, is a new version of an old cancer treatment tamoxifen. The company reported positive phase 2 clinical study results from Endoxifen study in ER-positive breast cancer patients that were between initial diagnosis and mastectomy. So in the coming weeks, ATOS is a stock worth watching.
Market Reaction:
On Tuesday, ATOS stock jumped 13.40% at $6.34 with more than 38.32 million shares, compared to its average volume of 19.33 million shares. The stock had moved within a range of $5.41 – 6.78 after opening the trade at $5.51. Over the past 52-week, the stock has been trading within a range of $0.81 – 9.80.
